This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willson, T. M. Articles by McDonnell, D. P. Search for Related Content PubMed PubMed Citation Articles by Willson, T. M. Articles by McDonnell, D. P.

Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone¹

Glaxo Wellcome Research and Development (T.M.W., P.B., H.R.B., S.A.J., B.H., H.S., S.W., D.M.), Research Triangle Park, North Carolina 27709; and the Department of Pharmacology and Cancer Biology, Duke University Medical School (J.D.N., B.L.W., I.A., D.P.M.), Durham, North Carolina 27710

Address all correspondence and requests for reprints to: Dr. D. P. McDonnell, Department of Pharmacology and Cancer Biology, Box 3813, Duke University Medical School, Durham, North Carolina 27710. E-mail: McDon016{at}acpub.duke.edu

The estrogen receptor (ER) mixed agonists tamoxifen and raloxifene have been shown to protect against bone loss in ovariectomized rats. However, the mechanism by which these compounds manifest their activity in bone is unknown. We have used a series of in vitro screens to select for compounds that are mechanistically distinct from tamoxifen and raloxifene in an effort to define the properties of an ER modulator required for bone protection. Using this approach, we identified a novel high affinity ER antagonist, GW5638, which when assayed in vitro functions as an ER antagonist, inhibiting the agonist activity of estrogen, tamoxifen, and raloxifene and reversing the "inverse agonist" activity of the pure antiestrogen ICI182,780. Thus, GW5638 appears to function as an antagonist in these in vitro systems, although in a manner distinct from other known ER modulators. Predictably, therefore, GW5638 alone displays minimal uterotropic activity in ovariectomized rats, but will inhibit the agonist activity of estradiol in this environment. Unexpectedly, however, this compound functions as a full ER agonist in bone and the cardiovascular system. These data suggest that the mechanism by which ER operates in different cells is not identical, and that classical agonist activity is not required for the bone protective activity of ER modulators.

This article has been cited by other articles:

				B. M. Wittmann, A. Sherk, and D. P. McDonnell Definition of Functionally Important Mechanistic Differences among Selective Estrogen Receptor Down-regulators Cancer Res., October 1, 2007; 67(19): 9549 - 9560. [Abstract] [Full Text] [PDF]

				J. H. Kim, M. H. Lee, B. J. Kim, J. H. Kim, S. J. Han, H. Y. Kim, and M. R Stallcup Role of aspartate 351 in transactivation and active conformation of estrogen receptor {alpha} J. Mol. Endocrinol., December 1, 2005; 35(3): 449 - 464. [Abstract] [Full Text] [PDF]

				D. P. McDonnell The Molecular Pharmacology of Estrogen Receptor Modulators: Implications for the Treatment of Breast Cancer Clin. Cancer Res., January 15, 2005; 11(2): 871s - 877s. [Abstract] [Full Text] [PDF]

				W. Shao, E. K. Keeton, D. P. McDonnell, and M. Brown Coactivator AIB1 links estrogen receptor transcriptional activity and stability PNAS, August 10, 2004; 101(32): 11599 - 11604. [Abstract] [Full Text] [PDF]

				M. A. Iannone, C. A. Simmons, S. H. Kadwell, D. L. Svoboda, D. E. Vanderwall, S.-J. Deng, T. G. Consler, J. Shearin, J. G. Gray, and K. H. Pearce Correlation between in Vitro Peptide Binding Profiles and Cellular Activities for Estrogen Receptor-Modulating Compounds Mol. Endocrinol., May 1, 2004; 18(5): 1064 - 1081. [Abstract] [Full Text] [PDF]

				J. M. Hall and K. S. Korach Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells Mol. Endocrinol., May 1, 2003; 17(5): 792 - 803. [Abstract] [Full Text] [PDF]

				P. Webb, P. Nguyen, and P. J. Kushner Differential SERM Effects on Corepressor Binding Dictate ERalpha Activity in Vivo J. Biol. Chem., February 21, 2003; 278(9): 6912 - 6920. [Abstract] [Full Text] [PDF]

				K. J. Ho and J. K. Liao Nonnuclear Actions of Estrogen Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1952 - 1961. [Abstract] [Full Text] [PDF]

				A. S. Levenson, K. M. Svoboda, K. M. Pease, S. A. Kaiser, B. Chen, L. A. Simons, B. D. Jovanovic, P. A. Dyck, and V. C. Jordan Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor Cancer Res., August 1, 2002; 62(15): 4419 - 4426. [Abstract] [Full Text] [PDF]

				R. C. Dardes, R. M. O'Regan, C. Gajdos, S. P. Robinson, D. Bentrem, A. De Los Reyes, and V. C. Jordan Effects of a New Clinically Relevant Antiestrogen (GW5638) Related to Tamoxifen on Breast and Endometrial Cancer Growth in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1995 - 2001. [Abstract] [Full Text] [PDF]

				D. P. McDonnell, C. E. Connor, A. Wijayaratne, C.-y. Chang, and J. D. Norris Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators Recent Prog. Horm. Res., January 1, 2002; 57(1): 295 - 316. [Abstract] [Full Text] [PDF]

				C. E. Connor, J. D. Norris, G. Broadwater, T. M. Willson, M. M. Gottardis, M. W. Dewhirst, and D. P. McDonnell Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor Cancer Res., April 1, 2001; 61(7): 2917 - 2922. [Abstract] [Full Text]

				D. J. Bentrem, R. C. Dardes, H. Liu, J. MacGregor-Schafer, J. W. Zapf, and V. C. Jordan Molecular Mechanism of Action at Estrogen Receptor {{alpha}} of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen Endocrinology, February 1, 2001; 142(2): 838 - 846. [Abstract] [Full Text] [PDF]

				M. Dutertre and C. L. Smith Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 431 - 437. [Abstract] [Full Text]

				C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]

				R. B. Dickson and G. M. Stancel Chapter 8: Estrogen Receptor-Mediated Processes in Normal and Cancer Cells J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 135 - 145. [Abstract] [Full Text] [PDF]

				H. Fuse, H. Kitagawa, and S. Kato Characterization of Transactivational Property and Coactivator Mediation of Rat Mineralocorticoid Receptor Activation Function-1 (AF-1) Mol. Endocrinol., June 1, 2000; 14(6): 889 - 899. [Abstract] [Full Text]

				J. Ashby Validation of In Vitro and In Vivo Methods for Assessing Endocrine Disrupting Chemicals Toxicol Pathol, May 1, 2000; 28(3): 432 - 437. [Abstract] [PDF]

				Q. Qu, H. Zheng, J. Dahllund, A. Laine, N. Cockcroft, Z. Peng, M. Koskinen, K. Hemminki, L. Kangas, K. Vaananen, et al. Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats Endocrinology, February 1, 2000; 141(2): 809 - 820. [Abstract] [Full Text] [PDF]

				J. M. Hall and D. P. McDonnell The Estrogen Receptor {beta}-Isoform (ER{beta}) of the Human Estrogen Receptor Modulates ER{alpha} Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens Endocrinology, December 1, 1999; 140(12): 5566 - 5578. [Abstract] [Full Text]

				A. L. Wijayaratne, S. C. Nagel, L. A. Paige, D. J. Christensen, J. D. Norris, D. M. Fowlkes, and D. P. McDonnell Comparative Analyses of Mechanistic Differences Among Antiestrogens Endocrinology, December 1, 1999; 140(12): 5828 - 5840. [Abstract] [Full Text]

				P. Webb, P. Nguyen, C. Valentine, G. N. Lopez, G. R. Kwok, E. McInerney, B. S. Katzenellenbogen, E. Enmark, J.-A. Gustafsson, S. Nilsson, et al. The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions Mol. Endocrinol., October 1, 1999; 13(10): 1672 - 1685. [Abstract] [Full Text]

				M. E. Nuttall, J. N. Bradbeer, G. B. Stroup, D. P. Nadeau, S. J. Hoffman, H. Zhao, S. Rehm, and M. Gowen Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats Endocrinology, December 1, 1998; 139(12): 5224 - 5234. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34) Endocrinology, November 1, 1998; 139(11): 4642 - 4651. [Abstract] [Full Text] [PDF]

				M. Sato, C. H. Turner, T. Wang, M. D. Adrian, E. Rowley, and H. U. Bryant LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 1 - 7. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]